España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Benzinga Pro
Data & APIs
Events
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Editas Medicine
EDIT
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$1.31
-0.03
-2.24%
At close: -
$1.31
-0.00370
-0.28%
After Hours: Dec 20, 6:11 PM EDT
Get Report
Comment
Editas Medicine (EDIT) Forecast
News
Earnings
Editas Medicine (EDIT) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Government Trades
Short Interest
Latest news for Editas Medicine (NASDAQ:EDIT) Stock
Editas Medicine Stock (NASDAQ: EDIT)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Tuesday, December 17, 2024
JPMorgan Downgrades Editas Medicine, Says Focus Shift Sparks Investor Caution
Vandana Singh
Monday, December 16, 2024
Evercore ISI Group Maintains Outperform on Ed...
Benzinga Newsdesk
JP Morgan Downgrades Editas Medicine to Under...
Benzinga Newsdesk
Friday, December 13, 2024
RBC Capital Maintains Sector Perform on Edita...
Benzinga Newsdesk
Walmart To Rally Over 22%? Here Are 10 Top Analyst Forecasts For Friday
Avi Kapoor
This Toll Brothers Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
Avi Kapoor
Editas Medicine shares are trading lower afte...
Benzinga Newsdesk
Barclays Maintains Equal-Weight on Editas Med...
Benzinga Newsdesk
Chardan Capital Downgrades Editas Medicine to...
Benzinga Newsdesk
Baird Maintains Outperform on Editas Medicine...
Benzinga Newsdesk
Editas Medicine Realigns Strategy to Focus on In Vivo Gene Editing, Targets Human Proof Of Concept By 2026
Vandana Singh
Stifel Downgrades Editas Medicine to Hold, Lo...
Benzinga Newsdesk
Thursday, December 12, 2024
Editas Medicine shares are trading higher aft...
Benzinga Newsdesk
Editas Medicine Initiates Cost Savings Measur...
Benzinga Newsdesk
Editas Medicine Says Ending Development Of Re...
Benzinga Newsdesk
Editas Medicine Plans Transition To An In Vi...
Benzinga Newsdesk
Wednesday, December 11, 2024
12 Analysts Have This To Say About Editas Medicine
Benzinga Insights
Wells Fargo Downgrades Editas Medicine to Equ...
Benzinga Newsdesk
Monday, December 09, 2024
Editas Medicine Presents Data From RUBY Trial...
Benzinga Newsdesk
Monday, November 25, 2024
Editas Medicine Downgraded: Analyst Sees Limited Near-Term Catalysts
Vandana Singh
Tuesday, November 05, 2024
Chardan Capital Maintains Buy on Editas Medic...
Benzinga Newsdesk
RBC Capital Maintains Sector Perform on Edita...
Benzinga Newsdesk
Stifel Maintains Buy on Editas Medicine, Lowe...
Benzinga Newsdesk
Truist Securities Maintains Buy on Editas Med...
Benzinga Newsdesk
Wells Fargo Maintains Overweight on Editas Me...
Benzinga Newsdesk
Barclays Maintains Equal-Weight on Editas Med...
Benzinga Newsdesk
Monday, November 04, 2024
Editas Medicine Q3 EPS $(0.75), Inline, Sales...
Benzinga Newsdesk
Wednesday, October 23, 2024
Evercore ISI Group Maintains In-Line on Edita...
Benzinga Newsdesk
Expert Outlook: Editas Medicine Through The Eyes Of 7 Analysts
Benzinga Insights
Correction: Wells Fargo Maintains Overweight ...
Benzinga Newsdesk
Wells Fargo Maintains Equal-Weight on Editas ...
Benzinga Newsdesk
Tuesday, October 22, 2024
Chardan Capital Maintains Buy on Editas Medic...
Benzinga Newsdesk
Editas Medicine Announced In Vivo Preclinical...
Benzinga Newsdesk
Monday, October 21, 2024
Editas Medicine And Genevant Sciences Enter N...
Benzinga Newsdesk
Thursday, October 03, 2024
Editas Medicine Reports Sale Of Certain Futur...
Benzinga Newsdesk
Thursday, September 19, 2024
RBC Capital Reiterates Sector Perform on Edit...
Benzinga Newsdesk
Tuesday, September 17, 2024
Where Editas Medicine Stands With Analysts
Benzinga Insights
Jones Trading Initiates Coverage On Editas Me...
Benzinga Newsdesk
Thursday, August 08, 2024
Editas Q2 Earnings & Revenues Miss Estimates, Stock Down
Zacks
Barclays Maintains Equal-Weight on Editas Med...
Benzinga Newsdesk
Editas Medicine shares are trading higher aft...
Benzinga Newsdesk
Truist Securities Maintains Buy on Editas Med...
Benzinga Newsdesk
Boot Barn To Rally Around 27%? Here Are 10 Top Analyst Forecasts For Thursday
Avi Kapoor
B of A Securities Upgrades Editas Medicine to...
Benzinga Newsdesk
Wednesday, August 07, 2024
Editas Medicine shares are trading lower afte...
Benzinga Newsdesk
Editas Medicine' Cash Balance Of $318.3M Is E...
Benzinga Newsdesk
Editas Medicine Q2 2024 GAAP EPS $(0.82) Miss...
Benzinga Newsdesk
Tuesday, June 18, 2024
Unveiling 5 Analyst Insights On Editas Medicine
Benzinga Insights
Oppenheimer Maintains Perform on Editas Medic...
Benzinga Newsdesk
Friday, June 14, 2024
Editas Medicine Unveils Updated Safety And Ef...
Benzinga Newsdesk
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch